

AMENDMENTS TO THE SPECIFICATION

IN THE SPECIFICATION:

Please amend the specification as follows:

At page 1, line 25:

Replace:

“The present inventor intensively studied to discover that by carrying out the gene therapy with a vector in which a fusion protein of the desired protein which should be produced in the body by the gene therapy and a glucagon C-terminal side 19-29 amino acid peptide, the blood level of the desired protein may be measured with high sensitivity using the glucagon peptide as a label, and that undesired physiological action or induction of immunological reaction due to the label peptide scarcely occurs, thereby completing the present invention.”

With:

--The present inventor intensively studied to discover that by carrying out the gene therapy with a vector in which a fusion protein of the desired protein which should be produced in the body by the gene therapy and a peptide that has the amino acid sequence shown in SEQ ID NO: 1, the blood level of the desired protein may be measured with high sensitivity using the glucagon peptide as a label, and that undesired physiological action or induction of immunological reaction due to the label peptide scarcely occurs, thereby completing the present invention.--

At page 2, line 5:

Replace:

“That is, the present invention provides a vector for gene therapy comprising an expression vector for mammalian cells and a nucleic acid coding for a fusion protein of glucagon C-terminal side 19-29 amino acid peptide region and a desired protein region which should be produced in the body, which vector can produce the fusion protein in the mammalian cells.”

With:

--That is, the present invention provides a vector for gene therapy comprising an expression vector for mammalian cells and a nucleic acid coding for a fusion protein of a peptide that has the amino acid sequence shown in SEQ ID NO: 1 and a desired protein region which should be produced in the body, which vector can produce the fusion protein in the mammalian cells.--

At page 2, line 15:

Replace:

“The present invention still further provides a method for quantifying a desired protein produced in the body or in cultured cells by expression of the vector for gene therapy, comprising quantifying, by immunoassay, the glucagon C-terminal side 19-29 amino acid peptide region in a test sample collected from a mammal or cultured mammalian cells to which the vector for gene therapy according to the present invention was administered.”

With:

--The present invention still further provides a method for quantifying a desired protein produced in the body or in cultured cells by expression of the vector for gene therapy, comprising quantifying, by immunoassay, a peptide that has the amino acid sequence shown in SEQ ID NO: 1 in a test sample collected from a mammal or cultured mammalian cells to which the vector for gene therapy according to the present invention was administered.--

At page 2, line 20:

Replace:

"The present invention still further provides a label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, consisting essentially of glucagon C-terminal side 19-29 amino acid peptide."

With:

"The present invention still further provides a label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, consisting essentially of a peptide that has the amino acid sequence shown in SEQ ID NO: 1.--

At page 2, line 24:

Replace:

"The present invention still further provides a method for labeling a protein produced in the body or in cultured cells, comprising labeling a desired protein produced in the body or in cultured cells with glucagon C-terminal side 19-29 amino acid peptide by expressing the desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, as a fusion protein with the glucagon C-terminal side 19-29 amino acid peptide as a label."

With:

"The present invention still further provides a method for labeling a protein produced in the body or in cultured cells, comprising labeling a desired protein produced in the body or in cultured cells with a peptide that has the amino acid sequence shown in SEQ ID NO: 1 by expressing the desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, as a fusion protein with the a peptide that has the amino acid sequence shown in SEQ ID NO: 1 as a label."

At page 3, line 3:

Replace:

"The present invention still further provides a use of glucagon C-terminal side 19-29 amino acid peptide as a label for a desired protein produced by expression of an

externally administered expression vector in the body of a mammal or in cultured mammalian cells.”

With:

“The present invention still further provides a use of a peptide that has the amino acid sequence shown in SEQ ID NO: 1 as a label for a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells.”

At page 3, lines 9:

Replace:

“Since the glucagon C-terminal side 19-29 itself does not have a physiological action and is well conserved in various mammals, it does not substantially induce an immunological reaction while it can be quantified by immunoassay with high sensitivity using a commercially available immunoassay kit.”

With:

--Since the peptide that has the amino acid sequence shown in SEQ ID NO: 1 itself does not have a physiological action and is well conserved in various mammals, it does not substantially induce an immunological reaction while it can be quantified by immunoassay with high sensitivity using a commercially available immunoassay kit.--

At page 5, line 18:

Replace:

“The “glucagon C-terminal side 19-29 amino acid peptide” which is expressed by the vector according to the present invention in the form of a fusion protein, means the peptide consisting essentially of totally 11 amino acids located from the 19th to 29th amino acid counted from the C-terminal of glucagon.”

With:

--The “peptide that has the amino acid sequence shown in SEQ ID NO: 1” which is expressed by the vector according to the present invention in the form of a fusion protein, means the peptide consisting essentially of totally 11 amino acids located from the 19th to 29th amino acid counted from the C-terminal of glucagon.--

At page 5, line 23:

Replace:

“Since the “glucagon C-terminal side 19-29 amino acid peptide” is used as a label of the desired protein, the peptide may be hereinafter referred to as “glucagon-originated label peptide” for convenience.”

With:

--Since the “a peptide that has the amino acid sequence shown in SEQ ID NO: 1” is used as a label of the desired protein, the peptide may be hereinafter referred to as “glucagon-originated label peptide” for convenience.--